Published Date: 21/02/2012
Category: Therapies & Markets
CSL Ltd - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, detailed financials, and corporate actions, providing a 360˚ view of the company.
Features:
CSL ltd
CSL Limited (CSL) is a biopharmaceutical group engaged in the R&D, manufacture, marketing and distribution of biopharmaceutical and allied products. CSL invests in the development of protein-based medicines for treating serious human diseases. The group operates globally through its human health businesses that include the operations of CSL Behring, CSL Bioplasma and CSL Biotherapies. CSL is headquartered in Victoria, Australia and employed about 10,000 people as of June 30, 2011. The group recorded revenues* of A$4,321.6 million (approximately $4,277.9 million) during the financial year ended June 2011 (FY2011), a decrease of 6.6% compared with FY2010. The operating profit of the group was A$1,212.6 million (approximately $1,200.4 million) during FY2011, a decrease of 13.2% compared with FY2010. The net profit was A$940.6 million (approximately $931.1 million) in FY2011, a decrease of 10.7% compared with FY2010. * Total revenues = sales revenues+ other revenues + other income